FI974432A - Grampositiivisten bakteerien käyttö rekombinanttiproteiinien ilmentämiseksi - Google Patents

Grampositiivisten bakteerien käyttö rekombinanttiproteiinien ilmentämiseksi Download PDF

Info

Publication number
FI974432A
FI974432A FI974432A FI974432A FI974432A FI 974432 A FI974432 A FI 974432A FI 974432 A FI974432 A FI 974432A FI 974432 A FI974432 A FI 974432A FI 974432 A FI974432 A FI 974432A
Authority
FI
Finland
Prior art keywords
gram
expression
recombinant proteins
positive bacteria
bacteria
Prior art date
Application number
FI974432A
Other languages
English (en)
Swedish (sv)
Other versions
FI974432A0 (fi
Inventor
Aldis Darzins
Stephen Whitehead
Dennis Hruby
Original Assignee
Univ Rockefeller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rockefeller filed Critical Univ Rockefeller
Publication of FI974432A0 publication Critical patent/FI974432A0/fi
Publication of FI974432A publication Critical patent/FI974432A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FI974432A 1995-06-07 1997-12-05 Grampositiivisten bakteerien käyttö rekombinanttiproteiinien ilmentämiseksi FI974432A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/472,244 US5821088A (en) 1990-05-11 1995-06-07 Use of gram-positive bacteria to express recombinant proteins
PCT/US1996/009965 WO1996040943A1 (en) 1995-06-07 1996-06-06 Use of gram-positive bacteria to express recombinant proteins

Publications (2)

Publication Number Publication Date
FI974432A0 FI974432A0 (fi) 1997-12-05
FI974432A true FI974432A (fi) 1998-02-02

Family

ID=23874715

Family Applications (1)

Application Number Title Priority Date Filing Date
FI974432A FI974432A (fi) 1995-06-07 1997-12-05 Grampositiivisten bakteerien käyttö rekombinanttiproteiinien ilmentämiseksi

Country Status (11)

Country Link
US (1) US5821088A (fi)
EP (1) EP0832252A1 (fi)
JP (1) JP2000512121A (fi)
KR (1) KR19990022476A (fi)
CN (1) CN1160462C (fi)
AU (1) AU711985B2 (fi)
CA (1) CA2224172A1 (fi)
FI (1) FI974432A (fi)
HU (1) HUP9902004A3 (fi)
NZ (1) NZ311902A (fi)
WO (1) WO1996040943A1 (fi)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737521B1 (en) * 1990-05-11 2004-05-18 The Rockefeller University Delivery and expression of a hybrid surface protein on the surface of gram positive bacteria
AUPM885194A0 (en) * 1994-10-14 1994-11-10 Council Of The Queensland Institute Of Medical Research, The Synthetic peptides and vaccines comprising same
US6100043A (en) * 1995-08-04 2000-08-08 The Perkin-Elmer Corporation Recombinant clone selection system
US5843656A (en) * 1995-08-07 1998-12-01 The Perkin-Elmer Corporation Recombinant clone selection system
AU6844696A (en) * 1995-08-07 1997-03-05 Perkin-Elmer Corporation, The Recombinant clone selection system
US6428784B1 (en) 1997-10-31 2002-08-06 New Horizons Diagnostics Corp Vaginal suppository for treating group B Streptococcus infection
US6277399B1 (en) 1997-10-31 2001-08-21 New Horizon Diagnostics Corporation Composition incorporating bacterial phage associated lysing enzymes for treating dermatological infections
US6432444B1 (en) 1997-10-31 2002-08-13 New Horizons Diagnostics Corp Use of bacterial phage associated lysing enzymes for treating dermatological infections
US6423299B1 (en) 1997-10-31 2002-07-23 Vincent Fischetti Composition for treatment of a bacterial infection of an upper respiratory tract
US20030082110A1 (en) * 1997-10-31 2003-05-01 Vincent Fischetti Use of bacterial phage associated lysing proteins for treating bacterial dental caries
US6056954A (en) 1997-10-31 2000-05-02 New Horizons Diagnostics Corp Use of bacterial phage associated lysing enzymers for the prophylactic and therapeutic treatment of various illnesses
US20030129146A1 (en) * 1997-10-31 2003-07-10 Vincent Fischetti The use of bacterial phage associated lysing proteins for treating bacterial dental caries
US7232576B2 (en) 1997-10-31 2007-06-19 New Horizons Diagnostics Corp Throat lozenge for the treatment of Streptococcus Group A
US6752988B1 (en) * 2000-04-28 2004-06-22 New Horizons Diagnostic Corp Method of treating upper resiratory illnesses
US6406692B1 (en) 1997-10-31 2002-06-18 New Horizons Diagnostics Corp Composition for treatment of an ocular bacterial infection
US6506595B2 (en) * 1998-03-31 2003-01-14 Itoham Foods Inc. DNAs encoding new fusion proteins and processes for preparing useful polypeptides through expression of the DNAs
ES2183601T3 (es) * 1998-08-17 2003-03-16 Europ Lab Molekularbiolog Metodo para purificar complejos de biomoleculas o proteinas.
AU2003252910B2 (en) * 1998-08-17 2006-07-06 Europaisches Laboratorium Fur Molekularbiologie (Embl) Method for purifying proteins and/or biomolecule or protein complexes
US6312955B1 (en) 1999-04-29 2001-11-06 Siga Pharmaceuticals Streptococcus gordonii strains resistant to fluorodeoxyuridine
US7063837B2 (en) * 1999-09-14 2006-06-20 New Horizons Diagnostics Corp Syrup composition containing phage associated lytic enzymes
US8128922B2 (en) * 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
US6686168B1 (en) 1999-11-04 2004-02-03 Zymogenetics, Inc. Cell surface display of proteins by recombinant host cells
AU1455501A (en) * 1999-11-04 2001-05-14 Zymogenetics Inc. Cell surface display of proteins by recombinant host cells
US7318928B2 (en) * 2000-08-01 2008-01-15 The Johns Hopkins University Molecular vaccine linking intercellular spreading protein to an antigen
US7342002B2 (en) * 2000-08-03 2008-03-11 The Johns Hopkins University Molecular vaccine linking an endoplasmic chaperone polypeptide to an antigen
NZ593617A (en) 2000-10-27 2012-04-27 Novartis Vaccines & Diagnostic Nucleic acids and proteins from streptococcus groups A & B
US7060687B2 (en) * 2001-02-07 2006-06-13 Genmont Biotechnology Co. Live vaccines for allergy treatment
CN100513548C (zh) * 2001-06-11 2009-07-15 应用超微系统股份有限公司 将AcmA型蛋白质锚融合体与微生物细胞壁材料进行结合的改良方法
EP1597348A4 (en) * 2002-08-26 2010-03-31 Novartis Vaccines & Diagnostic GENES OF STREPTOCOCCUS PRESERVED OR SPECIFIC
US7754467B2 (en) * 2003-01-29 2010-07-13 Osel, Inc. Surface expression of biologically active proteins in bacteria
US9701725B2 (en) * 2003-05-05 2017-07-11 The Johns Hopkins University Anti-cancer DNA vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
CA2532369C (en) 2003-07-31 2016-07-26 Chiron Corporation Immunogenic compositions for streptococcus pyogenes
US8945589B2 (en) * 2003-09-15 2015-02-03 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for Streptococcus agalactiae
EP2612679A1 (en) 2004-07-29 2013-07-10 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
KR100554347B1 (ko) * 2004-08-11 2006-02-24 재단법인서울대학교산학협력재단 비피도박테리아 속 유래 신호 펩타이드 및 이를 이용하여이형 단백질을 세포 밖으로 분비시키는 방법
CA2583803C (en) * 2004-10-08 2014-11-25 Giuliano Bensi Immunogenic and therapeutic compositions for streptococcus pyogenes
WO2006073970A2 (en) * 2005-01-06 2006-07-13 The Johns Hopkins University Rna interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by dna and transfected dendritic cell vaccines
US7456011B2 (en) * 2005-01-12 2008-11-25 Osel, Inc. Modified cyanovirin-n polypeptide
JP2008528004A (ja) * 2005-01-26 2008-07-31 ザ ジョンズ ホプキンス ユニバーシティー 突然変異癌タンパク質抗原およびカルレティキュリンをコードするプラスミドを用いる抗癌ｄｎａワクチン
US20110206692A1 (en) * 2006-06-09 2011-08-25 Novartis Ag Conformers of bacterial adhesins
US20100330105A1 (en) * 2006-08-22 2010-12-30 John Hopkins University Anticancer Combination Therapies
CA2668018A1 (en) * 2006-10-30 2008-09-12 Novartis Ag Immunogenic and therapeutic compositions for streptococcus pyogenes
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
US20080260765A1 (en) * 2007-03-15 2008-10-23 Johns Hopkins University HPV DNA Vaccines and Methods of Use Thereof
AU2008299376B2 (en) 2007-09-12 2013-02-28 Glaxosmithkline Biologicals S.A. GAS57 mutant antigens and GAS57 antibodies
KR101773114B1 (ko) 2007-12-21 2017-08-30 노파르티스 아게 스트렙토라이신 ｏ의 돌연변이 형태
US20090285861A1 (en) * 2008-04-17 2009-11-19 Tzyy-Choou Wu Tumor cell-based cancer immunotherapeutic compositions and methods
WO2010046778A2 (en) * 2008-10-21 2010-04-29 International Vaccine Institute Novel shigella frotein antigens and methods
EP2210935A1 (en) * 2009-01-19 2010-07-28 Deinove Methods for isolating bacteria
EP2462224B1 (de) * 2009-08-03 2017-05-10 c-LEcta GmbH Verfahren zur herstellung von nukleasen eines gram-negativen bakteriums unter nutzung eines gram-positiven expressionswirtes
US20140147873A1 (en) * 2011-03-03 2014-05-29 The Regents Of The University Of California Surface display of cellulolytic enzymes and enzyme complexes on gram-positive microorganisms
US9925257B2 (en) * 2011-09-23 2018-03-27 Forsyth Dental Infirmary For Children Vaccine and therapeutic delivery system
WO2013044059A2 (en) * 2011-09-23 2013-03-28 Forsyth Dental Infirmary For Children A vaccine and therapeutic delivery system
WO2014056199A1 (zh) * 2012-10-12 2014-04-17 清华大学 多肽的产生和纯化方法
FR3001729B1 (fr) * 2013-02-04 2015-03-06 Lab Francais Du Fractionnement Mutants du facteur x
US10182757B2 (en) * 2013-07-22 2019-01-22 The Rockefeller University System and method for optical detection of skin disease
CN111925426B (zh) * 2020-09-02 2022-03-29 天康制药(苏州)有限公司 一种产气荚膜梭菌α毒素突变体、表达系统、制备方法及应用
CN111978380A (zh) * 2020-09-02 2020-11-24 天康生物股份有限公司 野生型气肿疽梭菌细胞毒素a及其制备方法、应用和疫苗
CN111961121B (zh) * 2020-09-02 2022-05-31 天康制药(苏州)有限公司 产气荚膜梭菌ε毒素突变体蛋白及其制备方法、应用和疫苗
CN111944838B (zh) * 2020-09-02 2022-08-16 天康制药(苏州)有限公司 革兰氏阳性菌表达系统在表达腐败梭菌毒素中的应用、腐败梭菌α毒素的制备方法和疫苗
CN114958896B (zh) * 2021-11-12 2023-06-27 淮阴师范学院 一种提高乳酸片球菌的电转化效率的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013653A (en) * 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US4965197A (en) * 1987-06-12 1990-10-23 Massachusetts Institute Of Technology Coryneform expression and secretion system
DE3828666A1 (de) * 1988-08-24 1990-03-01 Behringwerke Ag Expression funktionsfaehiger homologer und heterologer proteine auf der aeusseren membran von e.coli und anderen gramnegativen bakterien
US5115102A (en) * 1989-07-21 1992-05-19 Monsanto Company Variant proteins and polypeptides possessing enhanced affinity for immobilized-metal affinity matrices
US5616686A (en) * 1990-05-11 1997-04-01 The Rockefeller University Polypeptide of a hybrid surface protein by bacteria
SE9101433D0 (sv) * 1991-05-13 1991-05-13 Marianne Hansson Recombinant dna sequence and its use
DE4122599C2 (de) * 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
ES2224097T3 (es) * 1992-03-13 2005-03-01 The Rockefeller University Suministro y expresion de una proteina de superficie hibrida sobre la superficie de bacterias gram positivas.
US5532142A (en) * 1993-02-12 1996-07-02 Board Of Regents, The University Of Texas System Method of isolation and purification of fusion polypeptides
WO1997008553A1 (en) * 1995-08-22 1997-03-06 The Regents Of The University Of California Targeting of proteins to the cell wall of gram-positive bacteria
GB9518323D0 (en) * 1995-09-07 1995-11-08 Steidler Lothar Materials and methods relating to the attachment and display of substances on cell surfaces

Also Published As

Publication number Publication date
WO1996040943A1 (en) 1996-12-19
CN1160462C (zh) 2004-08-04
US5821088A (en) 1998-10-13
CN1192245A (zh) 1998-09-02
CA2224172A1 (en) 1996-12-19
KR19990022476A (ko) 1999-03-25
FI974432A0 (fi) 1997-12-05
EP0832252A1 (en) 1998-04-01
MX9709325A (es) 1998-08-30
JP2000512121A (ja) 2000-09-19
HUP9902004A2 (hu) 1999-10-28
NZ311902A (en) 1998-12-23
HUP9902004A3 (en) 2000-04-28
AU6331096A (en) 1996-12-30
AU711985B2 (en) 1999-10-28

Similar Documents

Publication Publication Date Title
FI974432A (fi) Grampositiivisten bakteerien käyttö rekombinanttiproteiinien ilmentämiseksi
DK91192D0 (da) Protein
NO980915D0 (no) Rekombinante anti-CD4-antistoff egnet for human terapi
DE741187T1 (de) Rekombinante Obesitäts-(OB)-Proteine
NO940219D0 (no) Rekombinante antistoffer for human terapi
DE69630543D1 (de) Medizinische elektrodenleitung
FI963655A0 (fi) Polypeptidien parannettu eritys
DK19991D0 (da) Proteinpraeparationer
DE69528180T2 (de) Modifiziertes molkeprotein
DE69615996D1 (de) Behälter für medizinische Zwecke
NO976058L (no) Rekombinant mistellectin
BR9610239A (pt) Proteínas de fusão-alérgeno-xcd32
FI972030A0 (fi) Puhdistettuja papillomavirusproteiineja
ITRM920658A0 (it) Procedimento per la purificazione della proteina endotelina
DE69310373T2 (de) Expressionssystem für proteine
EE9600208A (et) Uued immuunomodulatoorse toimega peptiidid
FI972763A (fi) Mutanttiproteiineja
NO980375D0 (no) Humant MP52 Arg protein
BR9606756A (pt) Peptídeo
DK75393D0 (da) Production of protein
NO981052D0 (no) Peptidderivater
DK0713916T3 (da) Rekombinant beta-amylase
FI944997A0 (fi) Parannettu rekombinantti-proteiinien tuotanto
NO981051D0 (no) Peptidderivater
FR2732345B1 (fr) Peptide antibacterien